Gabapentin Capsules Recalled for Cross Contamination
Sun Pharmaceutical Industries is recalling Gabapentin Capsules, USP 300 mg, due to cross contamination. The recall affects approximately 12,876 bottles distributed nationwide.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: FDA classified this as Class III, which by definition indicates it is unlikely to cause adverse health consequences. The source text states only "cross contamination" as the reason without specifying what contaminant or harm is involved, and no illnesses or injuries are reported.
Plain-English summary
Sun Pharmaceutical Industries Inc. is recalling Gabapentin Capsules, USP 300 mg (Rx Only) due to cross contamination. The recalled product is available in 500-count bottles (NDC 62756-138-05) and 1000-count bottles (NDC 62756-138-04), distributed nationwide in the United States.
The recall covers specific lot numbers: HAD1458A (expires 04/2025), HAD2718A (expires 07/2025), and HAD3432A (expires 08/2025). Approximately 12,876 bottles are affected. This is a voluntary recall initiated by the manufacturer.
Patients taking the recalled gabapentin should contact their healthcare provider or pharmacist for instructions. Consumers with affected product should not stop taking their medication without medical guidance, as abrupt discontinuation may cause adverse health effects. Return unused product to the pharmacy.
The recalled product
- Product
- GABAPENTIN (GABAPENTIN)
- Brand
- GABAPENTIN
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Oral Prescription
- Hazard
- Affected units
- 12,876
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot # a) HAD1458A
- Exp. date 04/2025
- HAD2718A
- Exp. date 07/2025
- b) HAD3432A
- exp. date 08/2025
UPCs (5)
- 0362756204010
- 0362756202016
- 0362756138025
- 0362756137028
- 0362756139022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by SUN PHARMACEUTICAL INDUSTRIES INC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · GABAPENTIN
- ModerateGabapentin blister packs recalled after unknown impurity exceeded specification
FDA (Drugs) · 2025-10-29
- ModerateGabapentin capsules recalled after stability testing found unknown impurity out of specification
FDA (Drugs) · 2025-10-29
- ModerateGabapentin capsule bags recalled because blister packaging was inadequately sealed
FDA (Drugs) · 2025-07-09
- ModerateGabapentin Capsules 100 mg recalled for defective blister packaging
FDA (Drugs) · 2025-07-09
- ModerateGabapentin 600mg Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · cross contamination
See all →- CriticalCetirizine Hydrochloride Tablets Recalled Due to Cross Contamination with Ranitidine
FDA (Drugs) · 2026-07-29
- ModeratePrimidone tablets recalled over potential acemetacin cross-contamination at API manufacturer
FDA (Drugs) · 2026-06-17
- HighFly By Jing creamy sesame noodles may contain undeclared peanut
FDA (Food) · 2026-06-03
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets 50 mg Recalled for API Cross-Contamination
FDA (Drugs) · 2026-05-27